Psilocybin microdosing, a practice of consuming small amounts of mushrooms containing psilocybin for potential mental health benefits, has gained popularity despite limited research on its effects. In 2022, a longitudinal observational study was conducted with 1,112 participants who reported psilocybin microdosing to investigate its impact on mood, cognitive functioning, and physical coordination. The study revealed that psilocybin microdosing is linked to better mood and decreased symptoms of depression, anxiety, and stress, particularly among individuals with mental health concerns. As such, psilocybin microdosing holds promise as a potential alternative treatment for mental health issues.
This study is unique in that it is one of the largest and longest studies to the date of publishing the study on microdosing psilocybin, and one of the few to use a control group. It is also novel in its investigation of the effects of combining psilocybin with other active substances like lion's mane mushroom and vitamin B3 (niacin), and in its exploration of potential age-related differences in the effects of microdosing.
They also discovered that microdosers over the age of 55 who combined psilocybin with lion's mane mushrooms and vitamin B3 had improved psychomotor performance. Combining psilocybin with lion's mane mushroom and vitamin B3 did not affect changes in mood and mental health.
Furthermore, the subgroup of participants who reported mental health concerns at the time of baseline assessment exhibited an average reduction in depressive symptoms that resulted in a change from moderate to mild depression following approximately 30 days of microdosing psychedelics.